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Summary Statement—Consistent with the growing national focus on healthcare quality, the American College of
Cardiology Foundation (ACCF) and the American Heart Association (AHA) have taken a leadership role over the past
decade in developing measures of the quality of cardiovascular care by convening a joint ACCF/AHA Task Force on
Performance Measures. The Task Force is charged with identifying the clinical topics appropriate for the develop-
ment of performance measures and with assembling writing committees composed of clinical and methodological
experts in collaboration with appropriate subspecialty societies. The Task Force has also created methodology docu-
ments that offer guidance in the development of process, outcome, composite, and efficiency measures. Cardiovas-
cular performance measures using existing ACCF/AHA methodology are based on Class I or Class III guidelines rec-
ommendations, usually with Level A evidence. These performance measures, based on evidence-based ACCF/AHA
guidelines, remain the most rigorous quality measures for both internal quality improvement and public reporting.
However, many of the tools for diagnosis and treatment of cardiovascular disease involve advanced technologies,
such as cardiac imaging, for which there are often no underlying guideline documents. Because these technologies
affect the quality of cardiovascular care and also have the potential to contribute to cardiovascular health expendi-
tures, there is a need for more critical assessment of the use of technology, including the development of quality
and performance measures in areas in which guideline recommendations are absent.
The evaluation of quality in the use of cardiovascular technologies requires consideration of multiple parameters
that differ from other healthcare processes. The present document describes methodology for development of 2
new classes of quality measures in these situations, appropriate use measures and structure/safety measures. Ap-
propriate use measures are based on specific indications, processes, or parameters of care for which high level of
evidence data and Class I or Class III guideline recommendations may be lacking but are addressed in ACCF appro-
priate use criteria documents. Structure/safety measures represent measures developed to address structural as-
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ACCF/AHA Methodology for Technology Quality Measures September 27, 2011:1517–38pects of the use of healthcare technology (e.g., laboratory accreditation, personnel training, and credentialing) or
quality issues related to patient safety when there are neither guidelines recommendations nor appropriate use
criteria. Although the strength of evidence for appropriate use measures and structure/safety measures may not be
as strong as that for formal performance measures, they are quality measures that are otherwise rigorously devel-
oped, reviewed, tested, and approved in the same manner as ACCF/AHA performance measures.
The ultimate goal of the present document is to provide direction in defining and measuring the appropriate use—
avoiding not only underuse but also overuse and misuse—and proper application of cardiovascular technology and
to describe how such appropriate use measures and structure/safety measures might be developed for the pur-
poses of quality improvement and public reporting. It is anticipated that this effort will help focus the national dia-
logue on the use of cardiovascular technology and away from the current concerns about volume and cost alone to
a more holistic emphasis on value.6
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.1. Scope
here is an increasing demand for information on the quality,
st, and appropriate use of cardiovascular technologies,
cluding those used for imaging and therapeutic procedures.
addition, there is a need for the healthcare profession to
ke the lead in designing strategies to optimize the use of
chnology and provide ways to report this information
ternally.
The American College of Cardiology Foundation (ACCF)/
merican Heart Association (AHA) Task Force on Perfor-
ance Measures (Task Force) commissioned the ACCF/
HA Methodology for the Development of Quality Measures
r Cardiovascular Technology Writing Committee, which
as charged with developing a measurement methodology to
eet this demand. Although this document will determine the
quential process for developing these quality measures, no
commendations for using any specific technologies, de-
ces, or therapies will be made. The intended audience for
is document includes organizations considering the future
velopment of quality indicators for healthcare technology,
acticing clinicians, and specialists in cardiovascular medi-
ne.
Although much work has already been accomplished in
rformance measurement with respect to certain therapeu-
cs and processes of care, there is a need to better define
etrics for technologies, in which the linkage with outcomes
less well established. The focus of this document is the
ticulation of a formal methodology for developing quality
easures for cardiovascular technology when evidence-based
idelines recommendations are absent, termed appropriate
e measures (AUMs) and structure/safety measures (SSMs).
.2. Structure and Membership of the
riting Committee
he members of the writing committee included experienced
inicians and specialists in adult cardiovascular medicine,
ectrophysiology, interventional cardiology, cardiovascular
aging, and performance measures methodology.
.3. Relationships With Industry and
ther Entities
he work of the writing committee was supported exclusively
the ACCF and AHA. Writing committee members volun-
ered their time, and there was no commercial support for the
velopment of this performance methodology. Writing com-
ittee members were required to disclose in writing all
rrent financial relationships with industry and other entities,
well as those 12 months before initiation of the writing
fort, and verbally acknowledge these relationships to the
her members at each meeting (Appendix A), in accordance
ith standard ACCF and AHA reporting policies. In addition,
er reviewers of the document were asked to disclose
lationships with industry and other entities (Appendix B).
he parent Task Force makes every effort to avoid actual,
tential, or perceived conflicts of interest that may arise as a
sult of industry relationships or personal interests among ase writing committee. Because this is a methodology docu-
ent, the recommendations will not benefit or harm any
mpany. Consequently, the Task Force has determined that
embers’ relationships with pharmaceutical companies and
vice manufacturers are not relevant to the topic of this
cument. Authors’ comprehensive disclosure information,
hich includes information on relationships with industry and
her entities not relevant to this document, is available on-
e at http://content.onlinejacc.org/cgi/content/full/j.jacc.2011.
.007/DC1.
.4. Review and Endorsement
etween October 15, 2010, and November 1, 2010, this
cument underwent peer review, during which ACCF and
HA members and other healthcare professionals had the
portunity to review and comment on the text before its final
proval and publication. Forty-nine peer reviewers provided
0 individual comments.
The ACCF/AHA Methodology for the Development of
uality Measures for Cardiovascular Technology was ad-
ted by the respective boards of directors of the ACCF and
HA in May 2011. This methodology will be reviewed for
rrency once annually and updated as needed. It should be
nsidered valid until either updated or rescinded by the Task
orce.
.5. Abbreviations Used
hroughout the Report
MA–PCPI: American Medical Association—Physician
Consortium for Performance Improvement
UC: appropriate use criteria
UM: appropriate use measure
HR: electronic health record
D: implantable cardioverter-defibrillator
OE: level of evidence
QF: National Quality Forum
CI: percutaneous coronary intervention
CT: randomized controlled trial
SM: structure/safety measure
ask Force: ACCF/AHA Task Force on
Performance Measures
. Introduction
.1. Background
odern medicine has made great strides in improving both
ality of life and longevity in cardiovascular disease. Many
the tools used for the diagnosis and therapy of heart disease
volve advanced technologies. With each new technological
vance comes pressure for immediate implementation and
ssemination, often before evidence of efficacy has been
blished. The substantial advances in cardiovascular tech-
logies, accompanied by a concomitant growth in healthcare
penditures, have resulted in the need for more critical
sessment of use of technology.
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ACCF/AHA Methodology for Technology Quality Measures September 27, 2011:1517–38Existing methodology documents provide a wide range of
idance in the development of performance measures for
rdiovascular care based on ACCF/AHA practice guide-
nes, but substantial gaps persist for measuring performance
the use of cardiovascular technology, in which firm
idelines recommendations are often lacking. The purpose
this document is to define a process to address these gaps,
ilding on the current Task Force methodologies (1,2), and
define a methodology that will permit the development of
ality measurement in areas of cardiovascular technology,
ch as diagnostic imaging. This methodology is fundamen-
lly based on the Institute of Medicine healthcare quality
ms of providing safe, effective, patient-centered, timely,
ficient, and equitable care (3).
The primary goal of the present document is to provide
rection in measuring and improving the use of cardiovas-
lar technology and to describe how such measures might be
veloped for the purposes of quality improvement and
blic reporting to reduce not only underuse but also overuse
d misuse while also addressing proper and safe application.
collaboration with other involved stakeholders, physicians
ho care for patients with suspected or established cardio-
scular disease and persons expert in the acquisition and
terpretation of diagnostic tests are well positioned to con-
ibute to this process with the goal of achieving the best
ssible patient outcomes. This document is meant to ad-
nce the efforts of the profession, the AHA, and the ACCF
define and promote the highest-quality cardiovascular
actice and to ensure access to technologies for all patients
ho may benefit from them. It is anticipated that this effort
ill help focus the national dialogue on the use of cardiovas-
lar technology and away from the current concerns about
lume and cost alone to a more holistic emphasis on value.
he ultimate objective of the Task Force is to achieve the best
ssible patient outcomes, including the development of
easures that will promote optimal use of cardiovascular
chnology.
.2. Ongoing Quality Efforts
broad array of external stakeholders is focusing attention
the use of cardiovascular technology, including the Fed-
al Coordinating Council for Comparative Effectiveness
esearch (4), the Centers for Medicare and Medicaid Ser-
ces, the National Quality Forum (NQF) (5), the NQF
ational Priorities Partnership (6), the American Medical
ssociation–Physician Consortium for Performance Im-
ovement (AMA–PCPI), and the National Committee for
uality Assurance.
These efforts are complementary to many current ACCF/
HA quality efforts, many of which may also address
chnology:
.2.1. Clinical Practice Guidelines
CCF/AHA clinical practice guidelines are comprehensive
d literature based, often requiring years of preparation.
lthough in the past, guideline topics included procedures
.g., stress testing) or devices (e.g., implantable cardioverter-
fibrillators [ICDs]), the recent approach has been solely hasease based, with topics including stable angina pectoris,
ute myocardial infarction, and heart failure.
.2.2. Performance Measures
CCF/AHA performance measures distill guidelines recom-
endations into measures that reflect clinical care patterns as
commended by guidelines and are suitable for use for
countability. These measures focus on areas in which little
ntroversy exists related to the evidence supporting the
easure, valid measurement is feasible, and implementation
ill improve care. By definition, ACCF/AHA clinical perfor-
ance measures are based on recommendations in ACCF/
HA practice guidelines (1,2).
.2.3. Appropriate Use Criteria
CCF appropriate use criteria (AUC) provide information
out the best current use of tests and procedures in
ecific clinical scenarios encountered in clinical practice,
ch as imaging for risk assessment before noncardiac
rgery. AUC are literature based whenever possible but
so incorporate a rigorous Delphi process to create a
rmal expert consensus based on the principle that input
om a structured group of experts is more accurate than
nsensus from unstructured groups (7,8). Overall, AUC
tempt to define what, when, and for whom a test or
ocedure is (or is not) appropriate, on the basis of a
lance of risks and benefits.
.2.4. Competency and Training Documents
CCF competency and training documents define the neces-
ry knowledge base and training volume for a practitioner,
ually directed toward the performance of a specific proce-
re, such as transesophageal echocardiography or peripheral
scular intervention.
.2.5. Other Efforts
he ACCF and AHA have collaborated on a number of
her projects, including the development of data standards
d registries. Each organization also engages in addi-
onal quality initiatives, including publication of expert
nsensus documents and scientific position papers, sup-
rt of laboratory accreditation, physician credentialing,
d extensive medical education programs. Together these
forts all play a role in the optimal deployment of medical
chnology. However, they do not provide explicit metrics
eful for quality assessment, quality-improvement initia-
ves, or accountability (e.g., public reporting). The meth-
ology to close this gap is the subject of the present
cument.
.2.6. New Quality Measures for
ardiovascular Technology
he writing committee defines AUMs as those measures
sed on existing AUC documents related to use of technol-
y for which no guidelines recommendations are available.
SMs are defined as those measures related to the structural
d patient safety aspects of cardiovascular technology in
hich there are neither guidelines recommendations nor
UC but for which other documents describing best practice
ve been published or endorsed by the ACCF or the AHA or
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ocess.
.3. ACCF/AHA Performance Measures and
uality Metrics
hrough the activities of the Task Force, the ACCF and AHA
ve played a leadership role in the development of perfor-
ance measures and quality metrics for cardiovascular dis-
se for 10 years. The Task Force is guided by both a
ecific process for measure development, as well as estab-
shed methodologies for measure specification, which are
scribed in documents that provide guidance to performance
easure writing committees. Writing committees are in-
ructed to develop measures that conform to specific attri-
tes to the extent possible (Appendix C) (1,2). Detailed
ethodology has also been developed for measures of out-
mes (Appendix D) (9) and efficiency (Appendix E) (10).
lthough some attributes of measures may not be known
mpletely at the time of measure development (e.g., con-
ruct validity or feasibility of implementation), all should be
sessed during implementation. Not infrequently, field test-
g identifies issues that result in significant revision of
easures. Finally, specific methodology for combining vari-
s measures into composite measures has also been speci-
ed by the Task Force (11).
The lexicon of healthcare measurement can be confusing
d limiting. An important dichotomy differentiates measure-
ent for the purpose of “accountability,” for example, public
porting or pay-for-quality incentives, from those used
lely for internal quality-improvement efforts. Accordingly,
e Task Force has recommended that the term performance
easures apply to those measures of healthcare quality that
e appropriate for public reporting. These performance
easures developed by the Task Force are those measures
at have been developed using ACC/AHA methodology that
cludes a peer review and public comment process (12). This
ocess can include collaboration with the AMA–PCPI, the
enters for Medicare and Medicaid Services, the Joint
ommission, and/or NQF. Performance measures are then
stinct from quality metrics, which are intended for internal
ality improvement but not public reporting. The Task Force
fines such metrics as measures that have been developed to
pport self-assessment and quality improvement at the
ovider, hospital, and/or healthcare system level. These
etrics represent valuable tools to aid clinicians and hospitals
improving quality of care and enhancing patient outcomes
2). The ACCF/AHA position that some measures are well
ited for internal quality improvement but less well suited
r public reporting and accountability is supported by
hassin et al (13).
. Making a Case for Quality Measures
r Cardiovascular Technology
.1. Current Efforts in Quality Measures for
ardiovascular Technology
ardiovascular performance measures have historically reliedthe availability of Class I guideline recommendations, teually with Level of Evidence (LOE) A, that is, based on
ndomized controlled trials (RCTs), as illustrated in Table 1.
he methodology guiding the translation of guideline recom-
endations into performance measures has been explicitly
lineated by the ACCF/AHA, and this methodology pro-
des guidance to the writing committees (1,2).
This methodological constraint is both a strength and a
mitation. On the one hand, reliance on this LOE ensures that
easurement is limited to clearly efficacious processes of
re or proven outcomes. However, few trials provide evi-
nce to evaluate important parameters such as safety, ap-
opriateness, efficiency, patient satisfaction, and quality of
fe, or accepted best practices such as smoking cessation
unseling. This is especially true for the many diagnostic or
erapeutic procedures performed in patients with diagnosed
suspected cardiovascular conditions, which have not gen-
ally been investigated in an RCT format.
In the absence of such trials, specialists in cardiovascular
edicine and surgery have made substantial investments in
ditional data systems that allow benchmarked assessment
quality of care that can be used as performance measures.
ational registries (14) and databases (15) established by
ofessional organizations have enabled the capture of broad-
sed, patient-specific clinical data to foster these initiatives.
he Society of Thoracic Surgeons National Database ele-
ents and data were the basis of the NQF-endorsed National
oluntary Consensus Standards for Cardiac Surgery, adopted
2004. These 21 measures of quality underlie current
rformance measurement in cardiac surgery (16). However,
ey do not directly address appropriateness.
.2. Inclusion of Technology in Current
CCF/AHA Performance Measures
o date, the Task Force has commissioned 8 sets of perfor-
ance measures that have been published or are in develop-
ent (Table 2). Many have been developed in close collab-
ation with the AMA–PCPI, and some have been revised
nce first publication. Relatively few measures in these sets
cus even tangentially on use of technology, and those that
typically focus on underuse (e.g., documentation of left
ntricular systolic function assessments for heart failure and
ute myocardial infarction) or timeliness of technology
ployment (e.g., timeliness of primary percutaneous coro-
ry intervention [PCI]). Only recently have measures of
chnology overuse been proposed, and such measures have
t yet been approved for implementation. To a large extent,
is gap is related to the challenges in adapting the existing
CCF/AHA methodologies to assess the quality of technol-
y use.
Performance measures should be selected on the basis of
rong evidence of meaningful patient benefit and should be
rectly linked to positive patient outcomes (28). For exam-
e, ACCF/AHA performance measures include processes of
re that have the potential for patient harm when not
llowed, for example, the failure to prescribe beta blockers
llowing myocardial infarction. Thus, reperfusion therapy
r ST-elevation myocardial infarction fulfills the criteria for
technology-based performance measure. In some instances,
chnology measure development could follow the ACCF/
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ACCF/AHA Methodology for Technology Quality Measures September 27, 2011:1517–38HA methodology for performance measures even though
e process being measured lacks the requisite LOE A. One
ample is use of a technology when it is required to guide
plementation of a Class I, LOE A recommendation. This
gic was followed by the writing committee that developed
e ACC/AHA/AMA–PCPI heart failure measure set when it
eated the left ventricular systolic function assessment mea-
re (17). Measurement of ejection fraction is a Class I, LOE
recommendation in the “ACCF/AHA Guidelines for the
iagnosis and Management of Heart Failure in Adults” (29),
t this measurement is essential to identify patients in whom
lass I, LOE A recommendations apply for medical therapy
ble 1. Applying Classification of Recommendation and Level o
A recommendation with Level of Evidence B or C does not imply that the reco
not lend themselves to clinical trials. Although randomized trials are unavaila
eful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.ith beta blockers and angiotensin-converting enzyme inhib- foors or angiotensin receptor blockers. Similarly, the ACCF/
HA/AMA–PCPI chronic stable coronary artery disease
easurement set includes the symptom and activity assess-
ent measure (25,26). Assessment of a patient’s symptom
atus and level of activity is not supported by LOE A but is
y to the implementation of diagnostic and therapeutic
terventions that are Class I, LOE A recommendations.
lthough current performance measure documents have be-
n to incorporate such measures, an explicit methodology
r their development has not been developed. The current
cument fills this gap and formalizes the process needed for
velopment of performance measures and quality metrics
nce
ation is weak. Many important clinical questions addressed in the guidelines
re may be a very clear clinical consensus that a particular test or therapy is
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involvef Evide
mmend
ble, the
in diffe
dence Ar use of technology when LOE A evidence is lacking.
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evelopment of Quality Measures for
ardiovascular Technology
s noted above, the existing methodology for the develop-
ent of performance measures requires the identification of a
eatment or care process that has received a Class I, or more
rely, a Class III recommendation in ACCF/AHA practice
idelines (Figure 1, left side). Once it is determined that a
p in care is related to this recommendation, a measure is
rmulated and examined to ensure that it is attributable,
easurable, feasible, and reliable and will improve outcomes
,2). This process usually, but not always, requires LOE A.
his existing pathway provides a precedent for the creation of
select few technology performance measures, noted previ-
sly, that are either supported by LOE A or are necessary to
plement other measures supported by LOE A. The latter
isting technology measures based on LOE B or C (Table 1,
ght column) were created according to the current method-
ogy for performance measures and can serve as a guide for
ture technology performance measures that meet this high
andard. On the other hand, when no such linkages exist for
technology and where there is also no direct connection
tween the technology and the clinical outcomes that have
en the basis for performance measures, technology metrics
not meet the existing definition of performance measures.
this case, development of a formal methodology for
veloping performance measures and quality-improvement
etrics for cardiovascular technology is necessary and is the
ble 2. ACCF/AHA Performance Measure Sets
easure Topic Publication Date
No. of Tot
Measures/Me
art failure* 2005 (17); Currently
undergoing update
9
-elevation and non–ST-elevation
yocardial infarction
2006 (18); 2008 (19) 22
rdiac rehabilitation 2007 (20); 2010 (21) 6
rial fibrillation 2008 (22) 3
imary prevention of CVD 2009 (23) 13
ripheral arterial disease 2010 (24) 9
ronic coronary artery disease 2005 (25); 2011 (26) 9
pertension 2005 (27); 2011 (26) 1
*Measures sets in process that have undergone public comment and peer re
ACCF indicates American College of Cardiology; AHA, American Heart Assoc
ronary intervention; and STEMI, ST-elevation myocardial infarction.cus of the present document. A. Conceptualizing Quality Measures for
ardiovascular Technology
he evaluation of quality in the use of cardiovascular tech-
logies requires consideration of multiple parameters that
ffer from other healthcare processes. Hence, in addition to
e traditional performance measure pathway noted above,
e Task Force proposes 2 new classes of quality measures for
e in these situations and refers to these metrics as AUMs
d SSMs (Figure 1, right side). These measures will be
veloped by writing committees commissioned by the Task
orce that follow the methodology outlined in Section 5.4.
UMs and SSMs are conceptually intended to apply to uses
technology and procedures, including noninvasive diag-
stic testing, minimally invasive diagnostic and therapeutic
ocedures, and surgery. These are based on specific indica-
ons, technologies, processes, or strategies of care for which
ta to support a Class I or Class III guideline recommenda-
on are lacking but are supported by either AUC documents
n the case of AUMs) or other documents (in the case of
SMs) developed by ACCF or AHA writing groups or,
ternatively, by specialty professional societies (e.g., the
merican Diabetes Association, American Society of Echo-
rdiography, American Society of Nuclear Cardiology,
eart Failure Society of America, Heart Rhythm Society,
ociety for Cardiovascular Angiography and Interventions,
d Society of Cardiovascular Computed Tomography), pro-
ded that they have been endorsed by either the ACCF or
No. of
Technology
Measures/Metrics Technology Measure/Metric Name
2 ● Left ventricular systolic function assessment
(inpatient)
● Left ventricular systolic function assessment
(outpatient)
4 ● Evaluation of left ventricular systolic function
● Time to primary PCI
● Reperfusion therapy
● Time from ED arrival at STEMI referral facility
to ED discharge from STEMI referral facility in
patients transferred for primary PCI
● Time from ED arrival at STEMI referral facility
to primary PCI at STEMI receiving facility
among transferred patients
0 None
0 None
0 None
3 ● Lower-extremity vein bypass graft surveillance
● Measurement of ankle-brachial index
● Monitoring of abdominal aortic aneurysms
0 None
0 None
VD, cardiovascular disease; ED, emergency department; PCI, percutaneousal
trics
view.
iation; CHA and that they meet additional criteria noted in Section 6.
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ACCF/AHA Methodology for Technology Quality Measures September 27, 2011:1517–38onceptually, the SSM pathway could also be adapted for
ture measure development in other processes of care
yond cardiovascular technology when no LOE A guideline
commendation or AUC are available. Importantly, the devel-
ment of AUMs and SSMs must meet performance measure
d quality metrics standards, including demonstrating a gap in
re, formulation of metrics, and demonstration that these
etrics have measurability, feasibility, reliability, impact, etc.
nce developed, AUMs and SSMs would go through a similar
th of validation through the Task Force, including a period of
blic comment and peer review, and then the formal endorse-
ent of ACCF and AHA leadership. During this process it
ould be determined whether the proposed AUM or SSM is best
ited as a quality metric used only for internal improvement or
ould be considered for public reporting and accountability,
gure 1. Pathway for the development of AUMs and SSMs for ca
r Class III guidelines recommendations. AUMs are based on AU
hed documents (e.g., scientific, credentialing, or training stateme
editation statements) endorsed by the ACCF and/or AHA. AUMs
r endorsement for public reporting. This is also true for many for
blic reporting or accountability purposes and that is to be subm
ion must adhere to established ACCF/AHA methodology and mu
CCF and AHA for development of such measures. This includes
s in constituting the writing committee, formal peer review and p
CCF/AHA Task Force on Performance Measures in the review pr
merican College of Cardiology Foundation; AHA, American Heart
easures; and SSMs, structure/safety measures.milar to performance measures. foThe balance of benefit and harm in AUMs/SSMs can be
ore subtle than that found with usual performance mea-
res. In many cases, an AUM/SSM is developed in recog-
tion that traditional LOE A, although potentially feasible to
tain, is likely never to emerge for every indication or
plication of the technology. AUM/SSM development may
so include measures of outcomes, including procedural
mplications, patient experience of care, costs, and, in the
se of diagnostic tests, the impact of the technology on risk
ratification, management decisions, and efficiency of care
livery. In these instances, the balance of benefit and harm
often less clear-cut than for the targets of the usual
rformance measures.
When properly constructed with an appropriate methodol-
y, tested in implementation pilots, and supported by strong,
scular technology. Performance measures are based on Class
ments, and SSMs are based on other ACCF and/or AHA pub-
documents from other organizations (such as laboratory ac-
SMs should undergo measure testing before being submitted
rformance measures. Any measure deemed appropriate for
a national consensus organization for endorsement consider-
ply with all other standard policies and procedures of the
eration of members’ relationships with industry or other enti-
omment on the proposed measures, participation by the
and approval by ACCF and AHA leadership. ACCF indicates
iation; AUC, appropriate use criteria; AUMs, appropriate userdiova
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porting and accountability. An example of an imaging
UM that could be used for public reporting would be a
easure that reports rates of inappropriate imaging within
actices (10). Such a measure would be based on the AUC
r imaging developed by the ACCF using a formal, prospec-
vely defined consensus process (8).
In this respect, the imaging and revascularization AUC
veloped by the ACCF (8) can provide important guidance
d be embedded in the AUM pathway for development of
chnology measures (Figure 1).
The challenges in applying the existing ACCF/AHA mea-
rement methodologies for performance measures for cardio-
scular technology are detailed in Appendix F. The remainder
this document describes the proposed methodology of the
CCF/AHA Task Force for developing AUMs and SSMs.
. Proposed Methodology for the
evelopment of Quality Measures for
ardiovascular Technology
.1. Domains of Care
he writing committee has divided the quality measures for
rdiovascular technology into 2 distinct domains to reflect
e differing immediate goals of diagnostic and therapeutic
chnologies (information versus treatment) that will influ-
ce the associated measures of quality. Furthermore, the
isting care structure and its associated accreditation or certifi-
tion are often specific to diagnostic (e.g., echocardiography
rvices) or therapeutic (e.g., surgical care) technologies.
.2. Proposed Framework for the
evelopment of Quality Measures for
iagnostic Procedures
efining quality metrics for diagnostic tests is challenging for
veral reasons. Multiple components that involve different
dividuals and laboratory functions contribute to a “high-
ality” test result (30). Table 3 provides some examples of
rrent metrics proposed by professional societies and other
oups.
First, use of a particular test must be appropriate for the
tient and condition, and the benefits of its performance
ust outweigh the possible harm. Although ACCF and AHA
eated practice guidelines on diagnostic testing in the past
at recommended situations in which a diagnostic test might
fect patient management (31,32), these guidelines are no
nger current and have been withdrawn from use as ACCF/
HA policy statements. They have been replaced recently
ith AUC that indicate whether a certain test or tests (e.g.,
hocardiography) are appropriate or inappropriate for a
ven clinical scenario. AUMs can be developed around these
UC documents.
If a test is to be considered high quality, it must be
nducted according to the recommendations of the relevant
ofessional society and in consideration of any specifications
om the equipment manufacturer (if available). Those con-
cting the test must have an adequate level of skill, which is
ten demonstrated by fulfilling training requirements and/or rertification. Similarly, the testing laboratory must show that
can adequately perform all the technical processes associ-
ed with testing and that its equipment meets all technical
andards. This is usually established through accreditation.
lthough some diagnostic tests can be interpreted by those
ith standard medical training (e.g., hemoglobin value), other
sts (e.g., magnetic resonance imaging) require advanced
aining for performance and interpretation. Certification of
e interpreter is a common way of demonstrating such
aining and skill. SSMs could be developed around these
etrics of training, accreditation, and credentialing. In addi-
on, test results that depend heavily on interpretation (e.g.,
ress imaging) should be periodically examined at each
boratory to determine whether the test characteristics in
tual practice match published standard values. Ideally, for
ample, the test performance (sensitivity and specificity;
ea under the receiver operator curve) of stress imaging for
tecting coronary artery disease should be examined both at
e level of the laboratory and the persons interpreting the test
ble 3. Sample of Quality Domains and Measures
Potential Quality Measure Examples
ality Domain Diagnostic Therapeutic
ructure
Technical aspects
Professional
aspects
● Technician
certification
● Interpreter
certification
● Laboratory
accreditation
● Procedure provider
certification
● Laboratory
accreditation
ocess
Patient/technology
selection
● AUC documents
● Guidelines
documents
● Credentialing
documents
● Accreditation
documents
● AUC documents
● Guidelines
documents
● Credentialing
documents
● Accreditation
documents
Test or procedure
performance
● Demonstration of
test
characteristics to
be similar to
best practice
● Procedural
complications
Communication:
Laboratory to
referring provider/
medical
recordProvider to
patient
● Timely and
accurate
reporting of
results
● Timely
explanation of
test results
● Timely and
accurate
documentation of
procedure
● Timely explanation
of treatment results
if appropriate
tcome
Association with
care/outcome
● Altered diagnosis
or therapeutic
plans (indirect
linkage to
outcome)
● Short- and longer-
term impact of
therapy on clinical,
functional, and/or
cost outcomes
similar to best
practice
AUC indicates appropriate use criteria.sults.
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ACCF/AHA Methodology for Technology Quality Measures September 27, 2011:1517–38Once the diagnostic test is complete (including interpreta-
on if needed), the results need to be communicated to the
ferring provider in a timely manner. Such reporting should
llow standards for clarity, completeness, and definitiveness
0), and this could be another topic for AUM or SSM
velopment. A high-quality laboratory will also provide
cure but easy access for appropriate persons to view actual
st results. Finally, a high-quality test should contribute to
proved outcome. Proof of such a contribution is challeng-
g to obtain given the many factors that affect patient
tcome and the relatively small contribution that would be
pected from an individual diagnostic test. However, oppor-
nities to examine the test-outcome link may arise as the
option of electronic health records (EHRs) allows compi-
tion of large longitudinal clinical data sets. An intermediate
ep would be to determine, within an accountable unit,
hether a diagnostic test has a positive impact on down-
ream care by “reclassifying” patients who do or do not need
ecific therapy or procedures.
.3. Proposed Framework for the
evelopment of Quality Measures for
herapeutic Procedures
he design of quality measures for therapeutic/interventional
ocedures faces many of the same challenges as those for
agnostic procedures. Although certain aspects of procedural
tcome are readily defined and captured, evaluation of
ocedural success is nonetheless complex. Different catego-
es of interventions (e.g., vascular, valvular, and cardiac
rhythmia) have unique considerations for appropriateness,
dications, measures of success, and complications. The
riting committee recommends evaluating the performance
therapeutic/interventional procedures according to the
mponents of such procedures. One such classification
ight include the following:
Evaluation of patient characteristics to determine whether
an intervention is justified, as well as which intervention
is most appropriate when alternatives exist
Procedural or technical success
Communication and dissemination of procedural results
Outcomes associated with the procedure, both negative
(complications) and positive (clinical success)
The following text expands on these 4 components.
.3.1. Preprocedural Evaluation
reprocedural evaluation to determine whether a procedure is
stified requires several layers of investigation. First, indi-
dual patient characteristics must be assessed to determine
hether the performance of any procedure (versus no proce-
re) is necessary. This must include discussion of the
oblem with the patient and family members, explanation of
e benefits and risks of both performing and not performing
e procedure in general and for this individual, discussion of
ssible alternative therapies, and careful inquiry about
tient preferences. Once it is determined that therapy is
stified, it must be decided whether a procedural intervention
best, as opposed to other treatment modalities, such as
armacologic, nonpharmacologic, or behavioral therapy. In sume cases, one intervention must be weighed against another
CI versus coronary artery bypass surgery, or percutaneous
rial fibrillation ablation versus surgical maze procedure).
ecisions guiding therapeutic interventions depend in many
ses on the results of diagnostic technologies discussed
rlier in this document. Furthermore, in many cases, deter-
ination of the most appropriate therapy requires consider-
ion of the individual patient’s values and preferences and
equate patient education. In addition, once a decision is
ade to pursue a procedural intervention, further diagnostic
chnologies may be needed to gather additional information
cessary to maximize chances of procedural success.
.3.2. Determination of Short-Term (Technical) and
ong-Term (Clinical) Success
etermination of procedural success should be tailored to the
dividual procedure under consideration and may be simple
complex. In most cases, a distinction must be made
tween acute (short-term) and long-term success of an
tervention (Table 4). In general, short-term procedural
ccess is related to technical aspects of the procedure,
rrogate measures that are expected to correlate with long-
rm outcomes, and the absence of major procedure-related
mplications. Although developing such measures is not
sy, determining clinical or long-term success can be more
allenging to assess. Relief of symptoms, improved health-
lated quality of life, reduced need for medications or
spitalization, and improved survival can be reasonably
raightforward to assess in the individual patient, but other
tcomes are more difficult to assess directly and may require
mparison with the natural history of disease, which can
ly be defined in populations.
Immediate technical or procedural success may not predict
ng-term success. For example, assessment of quality of the
tcome following interventions for arrhythmias may be
allenging, because arrhythmias are often intermittent and
ay occur at random and/or without precipitating factors.
hus, assessment of the success of catheter-based (or surgi-
l) ablations requires knowledge of the number and fre-
ency of the patient’s arrhythmia episodes before the inter-
ntion to determine the duration of follow-up necessary to
sess whether the intervention has cured or ameliorated the
rhythmia. The use of surrogate endpoints such as inducibil-
y of tachycardia or termination of an ongoing tachycardia
ay serve as useful measures of immediate technical success
t are of uncertain value in predicting long-term clinical
ccess. Similarly, late complications, such as device infec-
on, or disease progression may complicate assessment of
ng-term success.
Even within a specific procedure, such as implantation of
ICD to prevent cardiac arrest/sudden death, the specific
dication may affect evaluation of success. In the case of
D implantation after resuscitation from cardiac arrest, the
sk of recurrent arrest has been fairly well defined. In the
se of prophylactic implantation of an ICD in a patient
ought to be at risk for sudden death, however, the actual risk
usually unclear. Further complicating assessment of suc-
ss in prevention of sudden death is the fact that the common
rrogate endpoint of “appropriate” ICD discharge is ac-
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September 27, 2011:1517–38 ACCF/AHA Methodology for Technology Quality Measuresowledged to considerably overestimate actual reduction of
dden death. Finally, whatever the metrics used, the metrics
ust have meaning from a patient perspective.
Once metrics are established, a final challenge in evaluat-
g the utility of interventions is assessment of adverse
tcomes. Recognition of acute complications is usually
vious. However, recognition of late complications may be
fficult due to inability to relate a given complication directly
a specific procedure. In addition, the person who per-
rmed the procedure or the laboratory in which the proce-
ble 4. Noninclusive Examples of Possible Indicators of Acute
ocedure Technical Success (Acute
I for chronic coronary artery
sease
● Degree of reduction in severity of coro
I for acute myocardial infarction ● Relief of coronary occlusion
● Improvement of coronary blood flow a
perfusion
anscatheter valve replacement
repair
● Successful deployment of prosthesis/d
● Reduction in transvalvular gradient
● Reduction in degree of valvular regurg
plantation of ICD ● Placement of device with leads in app
● Minimal patient discomfort associated
placement
plantation of cardiac
synchronization device
● Right and left ventricular leads optima
improve ventricular performance
lation of incessant ventricular
chycardia
● Termination of ventricular tachycardia
lation of intermittent ventricular
chycardia
● Prevention of inducible ventricular tach
programmed stimulation
rgical valve replacement or
pair
● Survival, resolution of hemodynamic a
ronary artery bypass surgery ● Survival, completeness of revasculariz
ICD indicates implantable cardioverter defibrillator; and PCI, percutaneous core was performed may not always learn of late complica- evons. Without this information, however, the true success of
e procedure, as well as evaluation of the quality of institu-
ons and physicians, cannot be assessed.
It should be apparent from this discussion that assessment
both short-term or technical success and long-term or
inical success of therapeutic interventions is complex and
allenging. As such, multiple factors and systems are re-
ired to evaluate optimal performance of therapeutic proce-
res. Table 4 provides some examples of possible indicators
r a variety of cardiovascular therapeutic procedures. How-
ronic Procedural Success
Clinical Success (Chronic)
ion ● Relief of myocardial ischemia
● Degree of reduction in patient’s symptoms
● Quality of life
● Patient’s experience of care
ardial
● Reduction in infarct size
● Prevention of reinfarction
● Improved left ventricular function
● Improved survival
● Quality of life
● Patient’s experience of care
● Degree of improvement in patient’s symptoms
● Reduced need for hospitalization
● Improved survival
● Quality of life
● Patient’s experience of care
position
nerator
● Appropriate treatment of potentially lethal ventricular
arrhythmias
● Absence of treatment for nonlethal arrhythmias
● Prolongation of life
● Quality of life
● Patient’s experience of care
ioned to ● Degree of improvement in patient’s heart failure symptoms
● Reduction in frequency of hospitalization
● Quality of life
● Patient’s experience of care
● Prevention or reduction in frequency of recurrent ventricular
tachycardia
● Improvement in survival
● Quality of life
● Patient’s experience of care
by ● Prevention or reduction in frequency of recurrent ventricular
tachycardia
● Improvement in survival
● Reduction in frequency of hospitalization
● Quality of life
● Patient’s experience of care
ity ● Improved survival
● Freedom from reintervention
● Symptomatic improvement
● Improvement in valve-related ventricular dysfunction
● Quality of life
● Patient’s experience of care
● Relief of angina
● Freedom from reintervention
● Improvement in long-term mortality
● Quality of life
● Patient’s experience of care
ntervention.and Ch
)
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uity of the illness, the skill of the operator, the experience
the support team, the health literacy of the patient, and the
cial determinants of health affecting quality of life, among
her issues.
.3.3. Communication
ccurate, timely, and clear communication of procedural
sults is critical to ensure optimal utilization and outcomes.
issemination of results can be viewed at several levels.
irst, the patient and family members must be told what was
complished, whether the expected technical goals of the
ocedure were met, the anticipated effect of the procedure on
e patient’s health, what restrictions may be imposed tem-
rarily, and what changes in medications (including addi-
ons or subtractions) may be expected.
The second level of communication is to other physicians
d providers involved in the patient’s care. Verbal and
ritten reports must clearly express positive and negative
sults of the procedure. If critical results of the procedure are
t plainly expressed in written reports, alterations in aspects
the patient’s care, such as medication adjustments, may not
carried out. For example, necessary changes in anticoag-
ant or antiplatelet therapy resulting from the procedure
ust be clearly stated, including the duration of these
anges.
The third level of communication is dissemination of
ocedural results in the hospital and patient’s medical record
that physicians caring for the patient in the future under-
and what procedure was performed, why it was performed,
d the observed outcome. Failure to accurately and com-
etely disseminate results could impact the patient’s out-
me as negatively as procedural failure.
.4. Sequential Process for Creating and
electing Quality Measures
onsistent development and testing of quality measures for
rdiovascular technology will follow a guiding framework
d ensure value and confidence in the end product. In an
tempt to standardize and define the sequence of decisions in
e construction of AUMs and SSMs, the writing committee
s outlined a set of steps that reflect a common process.
.4.1. Development of Measures
here are 2 general approaches to the construction of quality
easures. A proactive approach identifies a particular area in
hich it is believed a panel of metrics would improve patient
re and outcomes. In this case, the developers begin with a
lank slate” and try to create a comprehensive yet manage-
le set of metrics that will reflect quality in the area. The
tline below describes the sequence in such a process.
A reactive approach begins in response to a recognized
oblem. In this case, it might be expected that some evidence
a specific problem already exists, so the sequence of steps
ould begin at Step 4 below. Note that this approach may be
ss desirable than the proactive strategy, which is typically
ore comprehensive.
Select general technology target domain. Diagnostic or
therapeutic.Refine domain of care within targets as described in
Sections 5.2 and 5.3 of this document. Within these
domains, a number of possible subdomains could be
addressed with an AUM or SSM. These might be catego-
rized as process (appropriateness of use, guideline recom-
mended use, accuracy and reliability of results, respon-
siveness), structure (facilities, staffing), or outcome
(safety, complications, survival, resource utilization, qual-
ity of life, functional status, patient satisfaction).
Formation of writing committee. A hierarchy is consid-
ered for the development of quality measures for cardio-
vascular technology. It is understood that the evidence
base underlying ACCF/AHA guidelines is often of higher
quality than that used by AUC. Thus, if the procedure or
process of care is covered by an existing ACCF/AHA
guideline, then the guidelines recommendations should be
used to determine whether the topic is a candidate for a
formal performance measure. If the procedure or care
process is not covered by guideline recommendations but
is covered by AUC, then the AUC should be used to
evaluate whether a topic is eligible for an AUM. Alterna-
tively, if neither guideline recommendations nor AUC are
available, then the Task Force should use either formal
published statements of the ACCF or AHA or both or
published statements of other professional societies that
have been formally endorsed by the ACCF and/or the
AHA to determine if the topic is eligible for an SSM. In
either case, the Task Force should convene a measure
development writing committee that is balanced in its
composition (i.e., with fair representation of members who
do and do not perform the procedure under evaluation),
includes members with measure development methodol-
ogy experience, and adheres to existing ACCF and AHA
relationships with industry statements and strategies.
Identify a “gap in care” within the general domain. For
example, appropriateness of referral for angiography is a
specific example within the domain of patient selection for
diagnostics. Appropriateness of not referring for angiog-
raphy is another and more difficult example of a potential
focus of measurement.
Writing committee evaluation. The writing committee
should consider all the evidence available for a given
proposed measure. For example, if timeliness of reports is
thought to have an impact on patient care, evidence would
need to be generated to reflect that impact and define an
acceptable time frame. This process would need to be a
prospective, formal process incorporating all available
evidence (7). The writing committee should also consider
the potential anticipated benefits of creation of the mea-
sure on care process and patient outcome, in addition to
the potential adverse consequences that may result. Fi-
nally, the feasibility of consistently measuring the metric
must be considered. This will assess whether adequate
data systems are in place to collect the required data, as
well as the societal costs associated with collecting,
analyzing, and distributing the measure.
Measure definition. If the writing committee determines
that the benefits anticipated from measure development
outweigh the risks and costs, then the measure should be
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accountability and the unit of surveillance. With regard to
the former, most commonly a team (e.g., the clinic,
in-hospital caregivers, or noninvasive or procedural labo-
ratory) will be assessed. The unit of surveillance also helps
guide the specification of the measure. It would represent
the lowest level of data collection and would comprise the
denominator of the metric. It is not necessarily the same as
the unit of analysis. For example, the unit of analysis is the
patient when assessing appropriateness of patient selection
and also when assessing a treatment course; in the former
instance, the unit of surveillance is the patient, but it is
possibly each of several patient visits in the latter. The unit
of surveillance could be the result of an individual test in
a metric that assesses correctness or reliability of interpre-
tation, whereas the unit of analysis would depend on the
study design. Definition of the unit of surveillance is
necessary for data coding and implementation.
Measure refinement and ratification. The proposed
measure should be released for public comment as well as
peer review by appropriate internal and external experts.
After the writing committee has responded and revised the
measures, the measures should be referred to the Task
Force for a final methodological evaluation before referral
to the ACCF and AHA leadership for final approval.
.4.2. Testing of Measures
many cases, AUMs and SSMs will not have the benefit of
bstantial real-world information about important aspects of
asibility, reliability, and validity. (This is also true of many
rformance measures derived from evidence-based guide-
nes.) These parameters should then be assessed in a testing
ase. This testing should also attempt to identify any
intended consequences of measurement that might occur.
Feasibility. Any performance measure, AUM, or SSM
must be constructed so that collection of standardized data
across a wide range of institutions/practices is plausible
and allows for reasonably complete data sets. Currently,
the primary rationale for reliance on administrative data in
many performance measures is the relative ease with
which such data can be collected in large populations
across diverse practice settings. However, in many cases,
administrative data are either substantially inferior to
clinical data or simply inadequate for the development of
measures. Ultimately, increasing use of EHRs and stan-
dardized clinical registries is likely to enhance the extent
to which relevant clinical data will be available in the
scope necessary to develop performance measures without
reliance on administrative data.
Validity and reliability. As with performance measures
(1), AUMs and SSMs must be valid and reliable. At least
3 types of validity are important, including whether the
measure appears to measure what is intended (face valid-
ity), whether the measure captures the most important
aspects of the use of the technology (content validity), and
whether the measure correlates well with other measures
of similar aspects of care (construct validity). In the case
of outcome measures, appropriate risk adjustment is typ-
ically a critical aspect of validity. Reliability reflects the coextent to which a measure is reproducible in the same
population (1).
Unintended consequences. All quality measures, includ-
ing AUMs and SSMs, must be monitored for unintended
consequences. Measurement may require resources that
are diverted from other activities. Furthermore, measure-
ment may introduce changes into clinician behavior with
adverse consequences for patients. For example, a mea-
sure of the proportion of patients undergoing angiography
who have a positive stress test before the procedure would
provide incentives for the use of stress testing in all
patients being considered for angiography regardless of
the clinical appropriateness of the stress test itself. Thus,
testing of any measure should, to the extent possible,
include an assessment of potential consequences of
measurement.
. Additional Considerations in the
reation of Measures for
ardiovascular Technology
everal additional considerations are important components
the AUM development methodology, including oversight,
idence development, review, approval, implementation
ocesses, and relationship to other ACCF/AHA documents.
.1. Oversight
he responsibility and authority for the creation, review, and
omulgation of AUMs and SSMs is identical to that for
rformance measures and rests with the ACC/AHA Task
orce. Specifically, only the Task Force can convene a
riting committee, and that committee will work under the
idance and approval of the Task Force and in compliance
ith all other standard policies and procedures of the ACCF
d AHA for development of such measures. This includes
nsideration of members’ relationships with industry or
her entities in constituting the writing committee and broad
presentation on the committee, including persons represent-
g key stakeholder organizations and those with expertise in
ethodology. In considering whether to commission an
UM or SSM writing committee or add consideration of
UMs or SSMs to existing performance measure writing
mmittees, the Task Force should require that there is an
gent clinical or quality need for a measure(s) and that the
nefits would outweigh the harm of creating such measures.
.2. Evidence Development
lthough conventional performance measures generally re-
ire LOE A, it is recognized that potential topics for AUMs
SSMs will rarely be supported by this level of evidence,
t are still important to quality of care. In the absence of
gh-quality evidence, the Task Force may use LOE C as
nerated by a rigorous prospective process as previously
scribed. In practice, expert consensus as contained in
cuments developed by ACCF or AHA writing groups such
the AUC (in the case of AUMs) or other scientific or
edentialing documents (in the case of SSMs) will be
nsidered to meet this high standard and can be considered
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pics not generally in the purview of ACCF or AHA
cuments, similar consideration for SSM development will
granted to documents of specialty professional societies as
ted previously, provided that they have been endorsed by
e ACCF and/or AHA and that they meet these organiza-
ons’ established standards for document development, in-
uding an unbiased writing group, process transparency, peer
view, and organizational approval.
.3. Review, Approval, and
plementation Process
UMs and SSMs will be expected to undergo a review and
proval process similar to that for any performance measure
omulgated by the Task Force. This includes adherence to
tablished ACCF/AHA methodology as well as Task Force
licies and procedures, followed by formal peer review,
blic comment on the proposed measures, and approval by
CCF and AHA leadership. The writing committee also
rongly recommends that any AUM or SSM deemed appro-
iate for public reporting or accountability purposes be
bmitted to a national consensus organization for endorse-
ent consideration.
.4. Document Concordance
lthough performance measures are derived from ACCF/
HA guidelines, the ability to construct AUMs and SSMs
sed on other endorsed or approved documents means that
ey may address issues not yet included in guidelines, as
lowed by current ACCF and AHA policy for other state-
ents and documents. However, as new evidence is devel-
ed (whether LOE A, B, or C) and new documents are
ritten, it is expected that any relevant ACC and AHA
cuments, including AUMs and SSMs, would need to be
vised to remain concordant. If there is an area where
ad-to-head nonconcordance occurs, writing committees,
ith the review/approval of ACCF and AHA leadership, must
solve the issue before approving it as policy, after which the
n-concordant document will be updated and brought into
ncordance. In general, if evolving evidence leads to new
idelines recommendations that produce formal perfor-
ance measures, these would take precedence over AUMs or
SMs.
. Next Steps/Conclusion
he Task Force recognizes the need for performance mea-
res and quality metrics for cardiovascular technology. This
cument proposes a basic methodology for development of
ch measures for optimal use of technology. Because LOE A
often lacking, the Task Force has identified 3 distinct
thways for technology measure development, all falling
der the umbrella of quality measurements (Figure 1). First,
isting performance measure methodology can be used
hen the therapeutic procedure or diagnostic test is an
sential precursor or guide to implementation of a Class I
commendation or when there is an obvious patient safety
ncern. Existing performance measures have been devel-
ed in this manner. When this is lacking, a second pathwayproposed for development of such measures, termed
UMs, that includes reliance on existing AUC. When both
idelines recommendations and AUC are lacking, eviden-
ary standards based on formal expert consensus manifested
ACCF- or AHA-approved or endorsed standards can lead
development of SSMs. When properly constructed, tested
implementation pilots, and supported by strong consensus
ong multiple stakeholders, AUMs and SSMs have the
tential to achieve the standards for purposes of public
porting and accountability. In other cases, measures created
these alternative pathways may be more suitable for use in
ternal quality improvement.
Unlike development of structural and process performance
easures based on Class I guidelines recommendations, in
hich there is growing experience in clinical practice, devel-
ment of AUMs and SSMs presents unique challenges.
hese are related to lack of precedents, guidelines, and a
rong evidence base linking diagnostic testing or technical
pects of a procedure to clinical outcomes. These challenges
e seemingly less daunting for those therapeutic procedures
which outcomes data are available or guideline indications
e established. Nonetheless, measuring the quality of such
ocedures and their effectiveness at the level of the individ-
l physician or procedural team will represent new hurdles.
The writing committee strongly recommends that AUMs
d SSMs be developed under the aegis of the Task Force and
llow standard policies and procedures of the ACCF and
HA for development, approval, and promulgation of such
easures.
As such, the development of performance measures,
UMs, and SSMs for diagnostic and interventional proce-
res must adhere to the rigorous criteria established for such
easures. A needs assessment should identify a gap in care or
quality issue. Ideally, these measures should be tested and
aluated prospectively to confirm that that they provide
tisfactory feasibility, reliability, and validity before they are
plemented broadly. As is the case for all quality measures,
intended consequences are likely to arise and need to be
rutinized. Evaluation should also be conducted in a variety
practice settings, including solo practices, medium-sized
actices, and large practices, and also for inpatient proce-
res in hospitals serving communities of varying economic
sources in urban, suburban, and rural locations. Such testing
real-world settings will be informative in future modifica-
ons of measurement design. In particular, because the
ncept and development of AUMs and SSMs represent a
w paradigm, review of the early experience with quality
easures related to cardiovascular technology is essential to
sure that they contribute meaningfully to quality of care.
taff
merican College of Cardiology Foundation
avid R. Holmes, Jr, MD, FACC, ACCF President
hn C. Lewin, MD, Chief Executive Officer
net Wright, MD, FACC, Senior Vice President, Science
and Quality
C
M
A
A
Je
A
R
N
R
G
M
Jo
R
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
1531JACC Vol. 58, No. 14, 2011 Bonow et al.
September 27, 2011:1517–38 ACCF/AHA Methodology for Technology Quality Measuresharlene May, Senior Director, Science and Clinical Policy
elanie Shahriary, RN, BSN, Director, Performance Mea-
sures and Data Standards
merican College of Cardiology Foundation/
merican Heart Association
nsen S. Chiu, MHA, Specialist, Clinical Performance Measures
merican Heart Association
alph L. Sacco, MS, MD, FAAN, FAHA, AHA President
ancy Brown, Chief Executive Officer
ose Marie Robertson, MD, FACC, FAHA, FESC, Chief
Science Officer
ayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice
President, Office of Science Operations
ark D. Stewart, MPH, Science and Medicine Advisor,
Office of Science Operations
dy Hundley, Production Manager, Scientific Publishing,
Office of Science Operations
eferences
. Spertus JA, Eagle KA, Krumholz HM, et al. American College of
Cardiology and American Heart Association methodology for the selec-
tion and creation of performance measures for quantifying the quality of
cardiovascular care. J Am Coll Cardiol. 2005;111:1703–12.
. Spertus JA, Bonow RO, Chan P, et al. ACCF/AHA new insights into the
methodology of performance measurement: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Performance Measures. J Am Coll Cardiol. 2010;56:1767–82.
. Institute of Medicine. Crossing the Quality Chasm: A New Health System
for the 21st Century. Washington, DC: National Academy Press; 2001.
. Federal Coordinating Council for Comparative Effectiveness Research.
Report to the President and the Congress. Federal Coordinating Council
for Comparative Effectiveness Research. Available at: http://
www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf. Accessed June
10, 2011.
. National Quality Forum. Endorsing imaging efficiency standards. Avail-
able at: http://www.qualityforum.org/projects/imaging_efficiency.aspx.
Accessed June 13, 2011.
. National Quality Forum. National Priorities & Goals. Available at:
http://www.nationalprioritiespartnership.org. Accessed June 22, 2010.
. Physician Consortium for Performance Improvement. Position statement:
the evidence base required for measures development. Available at:
http://www.ama-assn.org/ama1/pub/upload/mm/370/pcpi-evidence-based-
statement.pdf. Accessed June 22, 2010.
. Patel MR, Spertus JA, Brindis RG, et al. ACCF proposed method for
evaluating the appropriateness of cardiovascular imaging. J Am Coll
Cardiol. 2005;46:1606–13.
. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical
models used for public reporting of health outcomes: an American Heart
Association scientific statement from the Quality of Care and Outcomes
Research Interdisciplinary Writing Group: cosponsored by the Council on
Epidemiology and Prevention and the Stroke Council. J Am Coll Cardiol.
2006;113:456–62.
. Krumholz HM, Keenan PS, Brush JE Jr, et al. Standards for measures
used for public reporting of efficiency in health care: a scientific statement
from the American Heart Association Interdisciplinary Council on Qual-
ity of Care and Outcomes Research and the American College of
Cardiology Foundation. J Am Coll Cardiol. 2008;118:1885–93.
. Peterson ED, DeLong ER, Masoudi FA, et al. ACCF/AHA 2010 position
statement on composite measures for healthcare performance assessment:
a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Performance Measures (Writing Com-
mittee to Develop a Position Statement on Composite Measures). J Am
Coll Cardiol. 2010;55:1755–66.. Bonow RO, Masoudi FA, Rumsfeld JS, et al. ACC/AHA classification of
care metrics: performance measures and quality metrics: a report of the
American College of Cardiology/American Heart Association Task Force
on Performance Measures. J Am Coll Cardiol. 2008;52:2113–7.
. Chassin MR, Loeb JM, Schmaltz SP, et al. Accountability measures:
using measurement to promote quality improvement. N Engl J Med.
2010;363:683–8.
. American College of Cardiology Foundation. National Cardiovascular
Data Registry. Available at: . Accessed February 24, 2010.
. Society of Thoracic Surgeons. National Databases: Society of Thoracic
Surgeons. Available at: http://www.sts.org/national-database. Accessed
June 10, 2011.
. National Quality Forum. National Voluntary Consensus Standards for
Cardiac Surgery. Available at: http://www.qualityforum.org/Publications/
2005/01/National_Voluntary_Consensus_Standards_for_Cardiac_Sur-
gery.aspx. Accessed February 24, 2010.
. Bonow RO, Bennett S, Casey DE Jr, et al. ACC/AHA clinical perfor-
mance measures for adults with chronic heart failure: a report of the
American College of Cardiology/American Heart Association Task Force
on Performance Measures (Writing Committee to Develop Heart Failure
Clinical Performance Measures). J Am Coll Cardiol. 2005;112:1853–87.
. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical
performance measures for adults with ST-elevation and non–ST-elevation
myocardial infarction: a report of the American College of Cardiology/
American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures on ST-Elevation
and Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol.
2006;47:236–65.
. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008
performance measures for adults with ST-elevation and non–ST-elevation
myocardial infarction: a report of the American College of Cardiology/
American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures for ST-Elevation
and Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol.
2008;52:2046–99.
. Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 perfor-
mance measures on cardiac rehabilitation for referral to and delivery of
cardiac rehabilitation/secondary prevention services. J Am Coll Cardiol.
2007;50:1400–33.
. Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010 update:
performance measures on cardiac rehabilitation for referral to cardiac
rehabilitation/secondary prevention services: a report of the American
Association of Cardiovascular and Pulmonary Rehabilitation and the
American College of Cardiology Foundation/American Heart Association
Task Force on Performance Measures (Writing Committee to Develop
Clinical Performance Measures for Cardiac Rehabilitation). J Am Coll
Cardiol. 2010;56:1159–67.
. Estes NA 3rd, Halperin JL, Calkins H, et al. ACC/AHA/Physician
Consortium 2008 clinical performance measures for adults with nonval-
vular atrial fibrillation or atrial flutter: a report of the American College
of Cardiology/American Heart Association Task Force on Performance
Measures and the Physician Consortium for Performance Improvement
(Writing Committee to Develop Clinical Performance Measures for Atrial
Fibrillation). J Am Coll Cardiol. 2008;51:865–84.
. Redberg RF, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009 perfor-
mance measures for primary prevention of cardiovascular disease in
adults: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures for Primary
Prevention of Cardiovascular Disease). J Am Coll Cardiol. 2009;54:
1364–405.
. Olin JW, Allie DE, Belkin M, et al. ACCF/AHA/ACR/SCAI/SIR/SVM/
SVN/SVS 2010 performance measures for adults with peripheral artery
disease: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Performance Measures, the
American College of Radiology, the Society for Cardiac Angiography
and Interventions, the Society for Interventional Radiology, the Society
for Vascular Medicine, the Society for Vascular Nursing, and the Society
for Vascular Surgery (Writing Committee to Develop Clinical Perfor-
mance Measures for Peripheral Artery Disease). J Am Coll Cardiol.
2010;56:2147–81.
. American College of Cardiology Foundation/American Heart Associa-
tion/American Medical Association-Physician Consortium for Perfor-
mance Improvement. Clinical Performance Measures: Chronic Stable
26
27
28
29
30
31
32
33
34
35
36
37
38
39
K
1532 Bonow et al. JACC Vol. 58, No. 14, 2011
ACCF/AHA Methodology for Technology Quality Measures September 27, 2011:1517–38Coronary Artery Disease. Chicago, IL: American Medical Association;
2005.
. Drozda JP Jr, Messer JV, Spertus J, et al. ACCF/AHA/AMA–PCPI 2011
performance measures for adults with coronary artery disease and
hypertension: a report of the American College of Cardiology Founda-
tion/American Heart Association Task Force on Performance Measures
and the American Medical Association–Physician Consortium for Per-
formance Improvement. J Am Coll Cardiol. 2011;58:316–36.
. American College of Cardiology Foundation/American Heart Associa-
tion/American Medical Association-Physician Consortium for Perfor-
mance Improvement. Clinical Performance Measures: Hypertension.
Chicago, IL: American Medical Association; 2005.
. National Quality Forum. Measure evaluation criteria. Available at:
http://www.qualityforum.org/Measuring_Performance/Submitting_
Standards/Measure_Evaluation_Criteria.aspx. Accessed February 21,
2010.
. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update:
ACCF/AHA guidelines for the diagnosis and management of heart failure
in adults: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. J Am
Coll Cardiol. 2009;53:1343–82.
. Douglas P, Iskandrian AE, Krumholz HM, et al. Achieving quality in
cardiovascular imaging: proceedings from the American College of
Cardiology-Duke University Medical Center Think Tank on Quality in
Cardiovascular Imaging. J Am Coll Cardiol. 2006;48:2141–51.
. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE
2003 guideline update for the clinical application of echocardiography—
summary article: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (ACC/ heAHA/ASE Committee to Update the 1997 Guidelines for the Clinical
Application of Echocardiography). J Am Coll Cardiol. 2003;42:954–70.
. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for
the clinical use of cardiac radionuclide imaging—executive summary: a
report of the American College of Cardiology/American Heart Associa-
tion Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to
Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide
Imaging). J Am Coll Cardiol. 2003;42:1318–33.
. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the
ACC/AHA clinical practice guidelines. JAMA. 2009;301:831–41.
. Murphy MK, Black NA, Lamping DL, et al. Consensus development
methods and their use in clinical guideline development. Health Technol
Assess. 1998;2:1–88.
. National Quality Forum. Guidance for evaluating the evidence related to
the focus of quality measurement. Available at: http://www.qualityforum.
org/Measuring_Performance/Improving_NQF_Process/Evidence_
Task_Force.aspx. Accessed February 2, 2011.
. Iglehart JK. Health insurers and medical-imaging policy: a work in
progress. N Engl J Med. 2009;360:1030–7.
. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective
coronary angiography. N Engl J Med. 2010;362:886–95.
. Schneider EC, Epstein AM. Influence of cardiac-surgery performance
reports on referral practices and access to care: a survey of cardiovascular
specialists. N Engl J Med. 1996;335:251–6.
. Werner RM, Asch DA, Polsky D. Racial profiling: the unintended
consequences of coronary artery bypass graft report cards. J Am Coll
Cardiol. 2005;111:1257–63.
EY WORDS: ACCF/AHA Performance Measures  quality assessment,
althcare  quality indicators, healthcare  technology, medical.
A
M
C
Ro
Co
Pa
Co
Al
Da
Je
El
Jo
T.
Pa
Ro
Fr
Er
Al
re
Th
re
en
m
Re
Affairs.
1533JACC Vol. 58, No. 14, 2011 Bonow et al.
September 27, 2011:1517–38 ACCF/AHA Methodology for Technology Quality Measuresppendix A. Author Relationships With Industry and Other Entiti
easures for Cardiovascular Technology
ommittee Member Employer/Title Consultant
bert O. Bonow,
-Chair
Northwestern University
Feinberg School of Medicine—
Chief, Division of Cardiology
None
mela S. Douglas,
-Chair
Duke University Medical
Center—Ursula Geller Professor
of Research in Cardiovascular
Diseases
None
fred E. Buxton Beth Israel Deaconess Medical
Center, Cardiovascular Medicine
Division–Professor of Medicine
None
vid J. Cohen Saint Luke’s Mid America Heart
Institute—Director,
Cardiovascular Research
None
ptha P. Curtis Yale University School of
Medicine, Section of
Cardiology—Assistant Professor
of Medicine
None
izabeth DeLong Duke Clinical Research
Institute—Professor
None
seph P. Drozda, Jr Sisters of Mercy Health
System—Director, Outcomes
Research
None
Bruce Ferguson, Jr Brody School of Medicine at
ECU—Professor of
Cardiovascular Sciences
None
ul A. Heidenreich Stanford VA Palo Alto Health
Care System—Assistant
Professor of Medicine
None
bert C. Hendel University of Miami Miller
School of Medicine—Director,
Cardiovascular Intensive Care
Unit and Hospital Director,
Cardiac Imaging and Outpatient
Services, Cardiovascular
Division
None
ederick A. Masoudi University of Colorado,
Denver—Associate Professor of
Medicine, Cardiology
None
ic D. Peterson Duke Clinical Research
Institute—Professor of
Medicine; Director,
Cardiovascular Outcomes
None
len J. Taylor Washington Hospital Center—
Co-Director, Noninvasive
Imaging
None
This table represents the relationships of committee members with industry an
lationships were reviewed and updated in conjunction with all meetings and/or
e table does not necessarily reflect relationships with industry at the time of pu
presents ownership of 5% or more of the voting stock or share of the busine
tity, or if funds received by the person from the business entity exceed 5% of
odest if it is less than significant under the preceding definition. Relationships
lationships in this table are modest unless otherwise noted.
ECU indicates East Carolina University; and VA, U.S. Department of Veteranses—ACCF/AHA Methodology for the Development of Quality
Speaker
Ownership/
Partnership/
Principal
Personal
Research
Institutional,
Organizational,
or Other
Financial Benefit
Expert
Witness
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
None None None None None
d other entities that were reported by authors to be relevant to this document. These
conference calls of the writing committee during the document development process.
blication. A person is deemed to have a significant interest in a business if the interest
ss entity, or ownership of $10,000 or more of the fair market value of the business
the person’s gross income for the previous year. A relationship is considered to be
that exist with no financial benefit are also included for the purpose of transparency.
A
M
Ma
Mi
Ha
Mi
Na
Ell
Da
Jo
He
Ka
Je
Cu
Ge
Va
Gr
Lin
Jil
W
Sc
Ch
Kr
Fr
Ra
Kw
St
Ro
Ke
Sh
No
E.
Br
R.
1534 Bonow et al. JACC Vol. 58, No. 14, 2011
ACCF/AHA Methodology for Technology Quality Measures September 27, 2011:1517–38ppendix B. Reviewer Relationships With Industry and Other Entities—ACCF/AHA Methodology for the Development of Quality
easures for Cardiovascular Technology
Peer Reviewer Representation Consultant Speaker
Ownership/
Partnership/
Principal Research
Institutional,
Organizational,
or Other
Financial Benefit
Expert
Witness
nuel D. Cerqueira Official Reviewer—AHA None None None None None None
chael H. Crawford Official Reviewer—AHA None None None None None None
rlan M. Krumholz Official Reviewer—ACCF Board of
Trustees
None None None None None None
chael R. McGuire Official Reviewer—ACCF Board of
Governors
None None None None None None
ncy Albert Content Reviewer—ACCF/AHA Task
Force on Practice Guidelines
None None None None None None
iott M. Antman Content Reviewer—Individual None None None None None None
niel S. Berman Content Reviewer—ACCF Imaging
Council
None None None None None None
hn F. Beshai Content Reviewer—ACCF Clinical
Electrophysiology/Electrocardiography
Work Group
None None None None None None
ather L. Bloom Content Reviewer—ACCF Clinical
Electrophysiology/Electrocardiography
Work Group
None None None None None None
vitha Chinnaiyan Content Reviewer—Society of
Atherosclerotic Imaging and Prevention
None None None None None None
nnifer E.
mmings
Content Reviewer—ACCF Clinical
Electrophysiology/Electrocardiography
Work Group
None None None None None None
orge A. Diamond Content Reviewer—ACCF/AHA New
Insights Into the Methodology of
Performance Measures
None None None None None None
sken Dilsizian Content Reviewer—Society of Nuclear
Medicine
None None None None None None
egg C. Fonarow Content Reviewer—Individual None None None None None None
da D. Gillam Content Reviewer—ACCF Imaging
Council
None None None None None None
l E. Jacobs Content Reviewer—North American
Society for Cardiovascular Imaging
None None None None None None
arren Janowitz Content Reviewer—Society of Nuclear
Medicine
None None None None None None
ott D. Jerome Content Reviewer—ACCF Quality in
Technology Work Group
None None None None None None
ristopher M.
amer
Content Reviewer—ACCF Imaging
Council
None None None None None None
ed M. Kusumoto Content Reviewer—Heart Rhythm
Society
None None None None None None
ymond Y.K.
ong
Content Reviewer—Society for
Cardiovascular Magnetic Resonance
None None None None None None
ephen J. Lavine Content Reviewer—American Society of
Echocardiography
None None None None None None
bert Lookstein Content Reviewer—Society of
Interventional Radiology
None None None None None None
nneth J. Nichols Content Reviewer—American Society of
Nuclear Cardiology
None None None None None None
aron-Lise T.
rmand
Content Reviewer—ACCF Quality in
Technology Work Group
None None None None None None
Magnus Ohman Content Reviewer—ACCF/AHA Task
Force on Practice Guidelines
None None None None None None
ian Olshansky Content Reviewer—ACCF Clinical
Electrophysiology/Electrocardiography
Work Group
None None None None None None
Heather Palmer Content Reviewer—American Medical
Association—Physician Consortium for
Performance Improvement
None None None None None None
(Continued)
ARa
L.
Ro
Sv
Ma
Su
M
Le
Ca
Da
Be
Pr
Ra
St
W
Ar
Pe
Ca
L.
Cl
E.
Ro
re
m
pe
un
m
an Heart Association.
1535JACC Vol. 58, No. 14, 2011 Bonow et al.
September 27, 2011:1517–38 ACCF/AHA Methodology for Technology Quality Measuresppendix B. Continued
Peer Reviewer Representation Consultant
hul S. Patel Content Reviewer—Society of
Interventional Radiology
None
Gregory Pawlson Content Reviewer—National Committee
for Quality Assurance
None
bert N. Piana Content Reviewer—ACCF Quality in
Technology Work Group
None
en Plein Content Reviewer—Society for
Cardiovascular Magnetic Resonance
None
rtha J. Radford Content Reviewer—Individual None
nil V. Rao Content Reviewer—Society for
Cardiovascular Angiography and
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None
ichael D. Shapiro Content Reviewer—Society of
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None
slee J. Shaw Content Reviewer—ACCF Task Force on
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Association—Physician Consortium for
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Society
None
verly Smulevitz Content Reviewer—American Society of
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None
em Soman Content Reviewer—American Society of
Nuclear Cardiology
None
ymond F.
ainback
Content Reviewer—ACCF Task Force on
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None
illiam G. Stevenson Content Reviewer—ACCF/AHA Task
Force on Practice Guidelines
None
thur E. Stillman Content Reviewer—North American
Society for Cardiovascular Imaging
None
ter L. Tilkemeier Content Reviewer—ACCF FOCUS Work
Group
None
rl L. Tommaso Content Reviewer—Society for
Cardiovascular Angiography and
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None
Samuel Wann Content Reviewer—Society of
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rformance Measures
Attribute Definition
eful in improving patient
tcomes
Evidence based The scientific basis of the measure is well
established
Interpretable The results of the measure are
interpretable by practitioners
Actionable The measure addresses an area under the
practitioner’s control
easure design
Denominator The patient group to whom this measure
applies is clinically meaningful
Numerator The definition of conformance for this
measure is clinically meaningful
Face validity The measure appears to measure what it
is intended to measure
Content validity The measure captures most meaningful
aspects of care
Construct validity The measure correlates well with other
measures of the same aspect of care
Reliability The measure is likely to be reproducible
across organizations and delivery settings
easure implementation
Feasibility The data required for the measure are
likely to be obtained with reasonable
effort and cost and within the period
allowed for data collection
ACCF indicates American College of Cardiology Foundation; and AHA,
erican Heart Association.
ppendix D. Preferred Attributes of Models Used for Publicly
eported Outcomes
Clear and explicit definition of an appropriate patient sample
Clinical coherence of model variables
Sufficiently high-quality and timely data
Designation of an appropriate reference time before which covariates are
derived and after which outcomes are measured
Use of an appropriate outcome and a standardized period of outcome
assessment
Application of an analytical approach that takes into account the
multilevel organization of data
Disclosure of the methods used to compare outcomes, including
disclosure of performance of risk-adjustment methodology in derivation
and validation samples
ppendix E. Standards for Measures Used for Public
eporting of Efficiency in Health Care
Integration of quality and cost
Valid cost measurement and analysis
No or minimal incentive to provide poor-quality care
mppendix F: Challenges in Applying
CCF/AHA Measurement Methodologies
Performance Measures for
ardiovascular Technology
everal issues make development of performance measures
r cardiovascular interventions, imaging procedures, and
her technological advances challenging. These special chal-
nges can be broadly classified as issues of 1) evidence
velopment; 2) association with outcome; and 3) measure-
ent feasibility, attribution, and application.
.1. Issues With Evidence Development
any diagnostic and therapeutic procedures evolve into
inical practice without well-run and adequately powered
CTs and thus lack specific Class I, LOE A data for several
asons. First, many diagnostic and therapeutic procedures
volve rapidly evolving technologies. Thus, it is often
allenging to determine the optimal time to perform trials
sessing these procedures. Ideally, a technology-based pro-
dure would be mature enough that chances of proving its
ficacy are maximized. Yet if a technology has already been
idely adopted, its evaluation in trials is rendered more
fficult due to acceptance into practice and a resulting lack of
uipoise on the part of clinicians and others.
A second challenge for evidence development for diagnos-
c and therapeutic procedures relates to their potential de-
ndence on operator skills. Unlike a drug whose dose and
livery can be standardized by protocols in an RCT evalu-
ion, procedural safety and benefits are commonly related to
e operator’s experience and technical skill. RCTs, which
pically include highly skilled operators, may overestimate
e safety and effectiveness of a technology in the hands of a
actitioner with a lower level of experience or skill.
A third concern is that RCTs must involve a large number
patients, often resulting in heterogeneous patient popula-
ons, and the relative benefit-risk of applying the procedure
ay vary greatly with different clinical indications. The result
that application of the trial results to what the clinician
ces—an individual patient rather than the “average” pa-
ent—can only be achieved by inference or expert interpo-
tion. This is true even of LOE A evidence incorporated into
idelines.
A fourth issue for evidence development in certain proce-
ral areas is one of ethics and practicality. For example,
ere are no direct RCTs demonstrating that the timeliness of
imary PCI for acute myocardial infarction is important or
fesaving. However, it would be unethical to randomize
tients to slower reperfusion therapy just to prove this point.
imilarly, delivery of diagnostic test reports in a timely and
mplete manner falls into a “common sense” category, and
would not be ethical to subject patients to an RCT
aluation.
These issues require that cardiovascular guidelines often
e less robust evidence (LOE B and C) to support their
commendations (33). Such evidence is deemed acceptable
some experts (7) for use in the development of perfor-ance measures, provided it is used in conjunction with all
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ospectively defined, formal consensus method. Informal or
hoc expert consensus methods are not acceptable because
ey do not provide the necessary rigor to reliably mitigate
e lack of RCT data, nor do they provide reliable, reproduc-
le LOE C data.
Expert opinion is not considered to be empirical evidence
cept when acquired using an unbiased expert group follow-
g a formal, disciplined process such as the Delphi method,
minal group technique, “modified nominal group tech-
que” or “modified Delphi,” or a consensus development
nference (34). The specified process must be transparent,
en to peer review, and publically reported. Other criteria
r the use of expert opinion in the development of quality
easures when no other evidence is available, as stated by the
QF, include a strong, explicit rationale for why the specific
ructure or process should be the focus of a quality measure
5). Finally, the experts must explicitly address the certainty
confidence that benefits to patients from the specific
ocess or structure greatly outweigh potential harm.
.2. Association With Outcomes and Costs
utcomes
evelopers of quality measures for diagnostic procedures
ust recognize the indirect link between testing and out-
mes, given the lack of direct therapeutic impact. Although
agnostic procedures can uncover information that may alter
tient management and ultimately lead to improved out-
mes, they are not directly therapeutic. Instead, any impact
outcomes depends on the clinician fulfilling the central
le of receiving and acting appropriately on the diagnostic
ta, including institution of effective evidence-based ther-
y. Furthermore, patients must adhere to therapeutic recom-
endations to preserve the link from diagnostic testing to
tcomes.
A parallel issue to the effectiveness or benefits side of
agnostic testing has to do with its safety or adverse
nsequences. Although some diagnostic procedures may
ve a low safety concern, others, such as procedures with
nizing radiation, may have adverse consequences for pa-
ent health. Furthermore, an inaccurate diagnostic study will
ve significant downstream consequences in terms of missed
agnosis of disease until an advanced stage on the one hand
unnecessary testing, procedures, and patient concern on the
her.
osts
lthough drawing a direct association between technological
ocedures and clinical outcomes can be challenging, there is
clear, direct association between the volume and complexity
diagnostic and therapeutic procedures and cost. Measure
velopment groups have traditionally not included economic
nsiderations in their construction of performance measures.
owever, the performance of procedures lacking significant
inical benefit can markedly drive up healthcare resource
ilization, either directly or through detection of “incidental
ndings.” In fact, diagnostic imaging has been the most
pidly increasing component of healthcare costs in patients
vered by Medicare (36). Although economic considerations
e usually not a key factor in the development of perfor- thance measures, cost provides a seemingly simple, measur-
le, and direct association with diagnostic and therapeutic
ocedures that may hold some appeal as a quality metric.
owever, the full understanding of the economics of diag-
stic testing and therapeutic procedures requires complex
odeling of the net costs. For example, the design of such
odels depends on the selection of the optimal design
rspective (e.g., that of the patient, society, or payer) for
hich no consensus exists. Cost considerations may also take
veral different approaches, such as the cost (and value) of
e technology, cost-effectiveness of the technology itself
rsus the comparative relative costs, and cost-effectiveness
hen implemented by different providers.
.3. Issues Surrounding Measurement
easibility, Attribution, and Application
easibility
feasible performance measure possesses the attribute that
e required data can be obtained in a timely manner with
asonable effort and cost. Some proposed diagnostic and
erapeutic AUMs/SSMs may lack this attribute. A tradeoff
ay exist between ease of data collection and quality of the
easure. For example, claims data provide ease of data
llection regarding procedural performance but lack fidelity
determine the clinical circumstances regarding testing
propriateness, accuracy, or association with subsequent
tcomes. Registries of diagnostic or therapeutic procedures
ovide an alternative to claims data. Procedure-specific
gistries (e.g., the National Cardiovascular Data Registry for
rdiac catheterization, PCI, carotid stenting, and ICDs)
ccessfully demonstrate the feasibility of high-quality, mul-
center data collection and its power to identify clinical
ality issues (37). Regional or even hospital-level pilots
ovide potentially feasible alternatives with enhanced orga-
zational relevance, although potentially limited in statistical
wer or external generalizability. These labor-intensive
forts generally have required either grant support or man-
tes from payers or regulatory bodies. An expanding future
ternative to stand-alone clinical registries is the harvesting
information on diagnostic and therapeutic procedure qual-
y directly from EHRs. However, such integrated EHR
stems would need to be ubiquitous, collect detailed data
ing standardized definitions, and share data for aggregation.
ithin present federal mandates for expanded use of EHR
stems, the opportunity to develop this mandate in an
vironment of standardized data definitions and uniform
ope could enable data aggregation on regional and national
vels.
ttribution
ssigning the responsibility for ensuring optimal use of
chnology or procedure performance is often challenging
d has ramifications for clinician autonomy, practice work
ow, reimbursement, and interprovider relationships (2).
ttribution for the selection of a procedure should involve
th the ordering physician and the performing laboratory.
eally, the primary accountability for the optimal use of a
st or procedure should be with the ordering physician, who
derstands the clinical scenario best, while acknowledging
at the performing laboratory may understand the strengths
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an the ordering physician. Additionally, processes such as
cision support are most useful when provided directly to
e referring clinician at the point of care, when the test/
ocedure is being ordered. Frequently, however, the concern
out overuse is focused where the procedure is being
rformed, because reimbursement may be denied if docu-
entation of clinical need cannot be provided. For example,
e imaging laboratory is at financial risk when inappropriate
ocedures are performed. Yet to deny service may not take
to account the clinician’s judgment about a specific patient
d may jeopardize the referring physician’s future use of
at service.
Clearly, joint attribution for the optimal use of diagnostic
sting and other procedures is needed. The proceduralist/
boratory must provide education and feedback to clinicians
out their referral patterns and offer suggestions in an
jective and professional manner. Simple denial of perfor-
ance of a procedure will not necessarily alter overuse or
isuse, because this may lead to use of other laboratories
ther than modification of procedure ordering. However,
boratory physicians must be engaged in the process, be-
use only this group realizes financial gain from providing
ese services. Learning communities have supportive labo-
tories that understand how to improve utilization and
mmunicate with referring physicians, and the ongoing use
clinical decision support can provide near-continuous
edback at the point of test/procedure ordering.
pplicability
he current feasibility of performance measurement is
mited for many diagnostic and therapeutic measures. 90lthough claims data can often capture whether a proce-
re was done, they cannot be used to explore the clinical
asons for why the procedure was performed, the results
the test, the accuracy of these results, or their impact on
bsequent clinical decision making. In this respect, EHRs
ay also aid in implementation of performance measures
facilitating collection of information on patient selec-
on and appropriateness.
Finally, as with all measures used for accountability or
blic reporting, technology measures may be subject to
intended consequences. The most obvious of these are
lated to underuse of technology in an attempt to curb
appropriate use. The application of AUC to prevent
eruse of diagnostic or interventional procedures could
sult in a reduction in their use, even among patients in
hom these procedures are not only appropriate but clearly
dicated. Thus, technological advances may be withheld
om patients who are likely to benefit from them. Imaging
amples include symptomatic patients not undergoing
agnostic evaluation for ischemic heart disease or asymp-
matic patients with valvular regurgitation not receiving
mely follow-up echocardiograms. Coronary artery bypass
rgery or PCI report cards could result in higher-risk
tients not receiving indicated myocardial revasculariza-
on, as has been speculated in the New York State
perience (38,39). Similarly, door-to-balloon measures
uld leave some patients without satisfactory reperfusion
r acute myocardial infarction if emergency personnel are
luctant to provide PCI to patients outside the optimal
-minute door-to-balloon time period.
